Innate Pharma S.A. (IPHA)

Innate Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 28, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	183	166	233	282	400	334
Market Cap Growth	44.90%	-29.08%	-17.19%	-29.50%	19.60%	-36.34%
Enterprise Value	144	107	180	196	283	177
Last Close Price	1.89	1.84	2.80	3.73	4.56	4.09
PS Ratio	12.30	7.95	3.43	4.58	14.24	3.92
PB Ratio	30.22	18.11	4.07	4.87	3.27	1.75
P/TBV Ratio	30.22	18.11	4.10	5.02	5.56	2.49
EV/Sales Ratio	9.72	5.15	2.65	3.19	10.07	2.07
EV/EBITDA Ratio	-	-	-	-	-	10.86
EV/EBIT Ratio	-	-	-	-	-	133.87
Debt / Equity Ratio	5.25	3.51	0.77	0.78	0.41	0.12
Debt / EBITDA Ratio	-	-	-	-	-	1.33
Asset Turnover	0.10	0.14	0.33	0.25	0.09	0.20
Quick Ratio	2.08	2.50	3.51	3.21	1.67	3.64
Current Ratio	2.21	2.60	3.73	3.38	1.73	3.81
Return on Equity (ROE)	-271.37%	-162.91%	-14.28%	-71.75%	-34.53%	-0.44%
Return on Assets (ROA)	-25.92%	-22.52%	-4.23%	-4.40%	-10.40%	0.19%
Return on Capital (ROIC)	-65.68%	-48.98%	-8.42%	-8.28%	-18.30%	0.33%
Return on Capital Employed (ROCE)	-79.80%	-66.10%	-9.30%	-10.40%	-25.50%	0.40%
Earnings Yield	-29.62%	-30.93%	-3.58%	-22.02%	-15.02%	-23.41%
FCF Yield	-26.23%	-4.56%	-15.58%	-7.46%	-16.89%	-19.27%
Buyback Yield / Dilution	-4.15%	-0.74%	-1.02%	-0.12%	-0.77%	-17.97%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q